



ROBERT WOOD JOHNSON
MEDICAL SCHOOL

University of Medicine & Dentistry of New Jersey



Contact: Michele Fisher
Media Relations Specialist
732/235-9872
fisherm2@umdnj.edu

CINJ Associate Director Receives Award at International Conference in New York
Dr. Joseph R. Bertino Honored at Lymphoma and Myeloma 2008 International Congress

New Brunswick, N.J., October 16, 2008 – Recognized by cancer specialists from around the globe, a noted leader at The Cancer Institute of New Jersey (CINJ) will be honored tomorrow with the *John Ultmann Award for Contributions to Lymphoma*, which will be presented at the Lymphoma and Myeloma 2008 International Congress on Hematologic Malignancies in New York City. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

Joseph R. Bertino, MD, associate director and chief scientific officer at CINJ and university professor of medicine and pharmacology at UMDNJ-Robert Wood Johnson Medical School, will be recognized during the SASS Foundation for Medical Research Award Ceremony. The conference promotes discussion of the latest advances in lymphoma and myeloma, and is attended by leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research.

The award is named in honor of John Ultmann, MD, the former director of the University of Chicago Cancer Research Center, who died in 2000 from complications of lymphoma. Dr. Ultmann was an internationally recognized expert in Hodgkin's disease and non-Hodgkin's lymphoma, and is considered a pioneer in the areas of diagnosis, staging, and treatment. This prestigious award recognizes Dr. Bertino's outstanding contributions and dedication to cancer research and scientific inquiry.

Bertino, a Franklin Township resident, who also is an American Cancer Society professor, has been recognized internationally for his role in finding curative treatments in the areas of leukemia and lymphoma. He is the author and co-author of more than 400 scientific publications. His laboratory is engaged in the studies of drug resistance, the use of drug resistant genes to protect bone marrow from chemotherapy toxicity and finding drugs that are toxic to tumor stem cells.

About The Cancer Institute of New Jersey

The Cancer Institute of New Jersey is the state's first and only National Cancer Institute-designated Comprehensive Cancer Center, and is dedicated to improving the prevention, detection, treatment and care of patients with cancer. CINJ's physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice quite literally bringing research to life. The Cancer Institute of New Jersey is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School. To support CINJ, please call The Cancer Institute of New Jersey Foundation at 1-888-333-CINJ.

The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides a mechanism to rapidly disseminate important discoveries into the community. Partner Hospital: Robert Wood Johnson University Hospital. Affiliate Hospitals: Bayshore Community Hospital, CentraState Healthcare System, Cooper University Hospital*, Jersey Shore University Medical Center, JFK Medical Center, Morristown Memorial Hospital, Overlook Hospital, Raritan Bay Medical Center, Robert Wood Johnson University Hospital at Hamilton (CINJ-Hamilton), Saint Peter's University Hospital, Somerset Medical Center, Southern Ocean County Hospital, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center at Princeton. *Academic Affiliate

###